The global multiple system atrophy therapeutics market is witnessing steady growth, underpinned by technological advancements, rising awareness of neurodegenerative conditions, and increased healthcare investment. According to a recent market analysis, the market was valued at USD 137.3 million in 2023 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.4%, reaching USD 211.1 million by 2033.
MSA is a rare, rapidly progressing neurodegenerative disorder with no cure currently available. However, rising patient awareness and medical research funding have driven renewed interest in therapeutic options for the condition. Pharmaceutical companies and biotech innovators are racing to develop novel therapies, while diagnostic advancements—particularly in imaging technology—are helping detect MSA more effectively and earlier than ever before.
Discover How Market Trends Are Shaping Industries: Access Your Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16285
Increasing Prevalence and Improved Diagnostics Drive Market Expansion
The growth trajectory of the MSA therapeutics market is closely linked to the rising prevalence of neurodegenerative diseases globally. With aging populations and growing awareness about neurological health, more individuals are undergoing evaluations that lead to earlier and more accurate diagnoses of MSA and similar conditions.
Among the diagnostic tools available, Positron Emission Tomography (PET) scans emerged as the leading segment in 2023, accounting for a 34.6% revenue share. PET imaging enables clinicians to detect subtle changes in brain activity and plays a pivotal role in differential diagnosis—distinguishing MSA from conditions such as Parkinson’s disease.
Meanwhile, China is anticipated to register a CAGR of 4.1% through 2033, supported by rapid expansion in healthcare infrastructure, higher healthcare spending, and national awareness campaigns around neurodegenerative diseases.
A Competitive Industry Landscape Fueled by R&D and Strategic Collaborations
Innovation and collaboration remain central themes in the MSA therapeutics sector. Leading pharmaceutical companies are forging partnerships to fast-track drug development and licensing efforts aimed at modifying disease progression and improving patient outcomes.
One notable collaboration includes the partnership between Teva Pharmaceutical Industries Ltd. and MODAG GmbH, which focuses on the development of MODAG’s lead compound anle138b and its derivative sery433. These compounds are being tested for their potential to modify the course of neurodegenerative diseases by targeting pathological alpha-synuclein oligomers—a hallmark in MSA pathophysiology.
Other key industry players contributing to market dynamism include Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc., Newron Pharmaceuticals SpA, and Stealth BioTherapeutics Corp. These organizations are increasingly directing resources toward both therapeutic and diagnostic innovations to meet the demand for better patient care.
In April 2022, ProMIS Neurosciences, Inc. reached new milestones in its research on therapeutics targeting toxic oligomers—misfolded proteins linked to multiple neurodegenerative diseases, including MSA. Later that year, Biohaven Ltd. reported progress on its extracellular target degrader platform—licensed from Yale University—designed for a broad range of disease applications, including neurological disorders.
Soaring Demand for Market Information: Uncover Detailed Trends and Insights in Our Report! https://www.futuremarketinsights.com/reports/multiple-system-atrophy-msa-therapeutics-market
Regional Growth Insights
North America currently dominates the MSA therapeutics market, thanks to its robust healthcare infrastructure, well-established pharmaceutical sector, and widespread adoption of advanced diagnostic tools. Moreover, recent product launches and substantial R&D investments further cement the region’s leadership position.
Europe, meanwhile, is emerging as a strong contender, bolstered by increased funding in research and innovation through national and pan-European initiatives. The region’s commitment to tackling rare diseases—combined with its well-developed regulatory landscape—makes it a strategic hub for clinical trials and early-stage development of MSA therapeutics.
Developing economies across South and East Asia are also making notable contributions, fueled by public-private partnerships and healthcare reforms aimed at reducing the burden of chronic diseases. As these regions continue to modernize their healthcare systems, they present substantial opportunities for market entrants and investors.
Market Opportunities and Future Outlook
The MSA therapeutics market is poised for continued growth, driven by several factors:
- Emerging Drug Launches: The industry anticipates a wave of novel drug introductions as several leading therapeutics approach patent expirations, opening the door for generic and biosimilar competition.
- Government Support: Governments worldwide are recognizing the public health implications of neurodegenerative diseases and are responding with funding, public awareness campaigns, and policy support for R&D initiatives.
- Healthcare Investment in Developing Countries: The rise in healthcare budgets and improved access to diagnostic facilities in emerging markets creates a fertile ground for expansion.
- Increased Capacity: Manufacturers are scaling up production to meet anticipated demand, with many focusing on optimizing supply chains and minimizing development cycles.
Market Segmentation Snapshot
The MSA Therapeutics Market is categorized based on Type, Diagnosis, and Region:
By Type:
- Parkinsonian
- Cerebellar
By Diagnosis:
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Single Photon Emission Computed Tomography (SPECT)
- Tilt Table Test
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa (MEA)
Expert Insights
“Growing healthcare spending and increase in the prevalence of neurological disorders are expected to radically transform the multiple system atrophy therapeutics market in the coming years,” said an analyst at Future Market Insights (FMI). “As innovations continue to reshape the treatment landscape, stakeholders must remain agile and adaptive to harness the evolving market potential.”
As the world grapples with an aging population and the rising burden of neurodegenerative conditions, the Multiple System Atrophy (MSA) Therapeutics Market stands at a crucial inflection point. With patient needs, innovation, and investment aligning more closely than ever before, the next decade promises significant breakthroughs in diagnosis, treatment, and quality of life for MSA patients worldwide.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
